ENTITY
SMARTSCORE: 2.8/5

ABLBio (298380 KS)

11
Analysis
Health CareSouth Korea
ABLBio, Inc. operates as a drugs development company. The Company develops and manufactures neurodegenerative diseases therapeutic drugs, oncology therapeutic drugs, and other products. ABLBio markets its products throughout Korea.
more
20 Jul 2025 23:05

KRX Foreign Holding Weekly (Jul 18th): Samsung Electronics, Sksquare, SK Hynix, Naver

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Samsung Electronics, Sksquare, SK Hynix, Naver.

Logo
115 Views
Share
bullishABLBio
07 Apr 2025 15:13

ABLBio (298380 KS): Continued License Out Deals and Milestone Payment Realization to Feed Pipeline

​ABLBio partners with GSK to develop CNS treatments using Grabody-B, potentially receiving up to £2.075B in milestone payments and royalties....

Logo
351 Views
Share
29 Jun 2025 00:30

APAC Healthcare Weekly (June 29)- RemeGen, Innovent, Daiichi, SanBio, Otsuka, Chugai, Glenmark

Last week couple of Chinese companies signed outlicensing deals with international players. Innovent got weight loss drug approval in China....

Logo
474 Views
Share
04 May 2025 00:30

APAC Healthcare Weekly (May 4)- Takeda Pharma, Samsung Biologics, Celltrion, Dr. Reddy’s, Medanta

Takeda retained top slot in domestic market. Samsung Biologics signed major CDMO deal with US client. Celltrion got approval to start trial of...

Logo
614 Views
Share
20 Apr 2025 23:05

KRX Foreign Holding Weekly (Apr 18th): Hdhms, Celltrion, SK Hynix, Samsung Electronics

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Hdhms, Celltrion, SK Hynix, Samsung Electronics,...

Logo
444 Views
Share
x